Financial PerformanceGRI Bio has sufficient cash into 2026, bolstered by $3 million in cash and $5 million raised, providing a solid financial foundation.
Product DevelopmentGRI Bio's development of GRI-0621 for Idiopathic Pulmonary Fibrosis targets a condition with large market potential, affecting approximately 140,000 patients in the U.S.
Safety ProfileThe reported data demonstrate GRI-0621 is safe and well-tolerated in the first 12 patients evaluated, de-risking upcoming data readouts.